This integrated preclinical/clinical program application will test CpG oligodeoxynucleotides (CpG ODN) for their ability to enhance host defenses against the human immunodeficiency virus. Our proposals comprise basic research projects based at Case Western Reserve University and Rush Medical College, primate studies at University of California Davis and clinical trials at Case Western Reserve University. The overall goals of these projects are to determine: (1) how CpG ODN (which are known to stimulate innate host defenses) modify host innate and adaptive immune responses in vitro; (2) how CpG ODN can be used as an adjuvant to enhance SIV specific immune responses in a rhesus macaque model; and (3) demonstrate that CpG ODN is an effective vaccine adjuvant in humans. Project 1 """"""""Modulation of APC by CpG ODN: Cytokine Signaling and T Cell Presentation in Human and Murine Systems"""""""" will delineate the nature of the stimulatory and inhibitory activities of CpG ODN on antigen presenting cells. Murine and human models will be utilized to dissect the role of IFNalpha/beta induction by CpG to determine how IFNalpha/beta can enhance and down modulate APC function in mice and in HIV-infected humans and in controls. Project 2 """"""""CD1d Restricted T (NKT) Cell Interaction with CpG ODN"""""""" will examine the mechanisms whereby CpG ODN expands the population of NKT cells, which are critical to bridging innate and adaptive immunity, in vitro and in vivo. Project 2 also will test the hypothesis that CpG induced activation of plasmacytoid dendritic cells determines the immunomodulatory activity of NKT cells as assessed by IL-4, IFN-gamma, and GM-CSF production. Project 3 """"""""CpG ODN for Therapeutic HIV Vaccines: Non Human Primate Studies"""""""" will evaluate how CpG ODN can enhance innate and adaptive antiviral immunity in rhesus macaques immunized with a killed SIV vaccine. The effects of this strategy on antiviral defenses will be evaluated by analytic treatment interruption. Concurrently, the effects of CpG ODN on NKT cell number and function and on IFN-alpha producing cells will be determined. The fourth project: """"""""Immunologic Effects of CpG ODN as Vaccine Adjuvant in HIV Infection"""""""" will test the hypothesis that CpG ODN enhances both the magnitude and breadth of pathogen-specific CD8 cell-mediated responses to subunit vaccines. These responses will be compared in HIV infected persons and healthy controls. In addition the effects of CpG ODN on APC function and on NKT cells in vivo will be examined. Overall, this IP/CP application will effectively integrate information gained from basic mechanistic studies into both animal models of HIV infection and human vaccine trials. This application will provide basic and clinical information on the potential use of CpG ODN as a novel immune based therapy for HIV infection and will provide the foundation on which to move forward into larger efficacy studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI055793-01
Application #
6673563
Study Section
Special Emphasis Panel (ZAI1-AM-A (M1))
Program Officer
Voulgaropoulou, Frosso
Project Start
2003-07-15
Project End
2006-12-31
Budget Start
2003-07-15
Budget End
2003-12-31
Support Year
1
Fiscal Year
2003
Total Cost
$717,332
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
McGinty, Tara; Mirmonsef, Paria; Mallon, Patrick W G et al. (2016) Does systemic inflammation and immune activation contribute to fracture risk in HIV? Curr Opin HIV AIDS 11:253-60
Nguyen, Thao P; Bazdar, Doug A; Mudd, Joseph C et al. (2015) Interferon-? inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling. J Leukoc Biol 97:1139-46
Jiang, Wei; Lederman, Michael M; Harding, Clifford V et al. (2011) Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells. J Immunol 186:2080-6
GenescĂ , Meritxell; Miller, Christopher J (2010) Use of nonhuman primate models to develop mucosal AIDS vaccines. Curr HIV/AIDS Rep 7:19-27
Wang, Yichuan; Blozis, Shelley A; Lederman, Michael et al. (2009) Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol 16:499-505
Montoya, Carlos J; Catano, Juan C; Ramirez, Zoraida et al. (2008) Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol 127:1-6
Montoya, Carlos J; Pollard, David; Martinson, Jeffrey et al. (2007) Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122:1-14
Montoya, Carlos Julio; Velilla, Paula Andrea; Chougnet, Claire et al. (2006) Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 120:138-46
Montoya, Carlos J; Jie, Hyun-Bae; Al-Harthi, Lena et al. (2006) Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol 177:1028-39
Anthony, Donald D; Yonkers, Nicole L; Post, Anthony B et al. (2004) Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 172:4907-16